Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.

0QNA

Basilea Pharmaceutica (0QNA)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:LSE:0QNA
DataOraFonteTitoloSimboloCompagnia
20/06/202407:15UK RegulatoryBasilea verpartnert Onkologie-Wirkstoffkandidat Lisavanbulin mit Glioblastoma FoundationLSE:0QNABasilea Pharmaceutica Ag
20/06/202407:15UK RegulatoryBasilea partners oncology drug candidate lisavanbulin with Glioblastoma FoundationLSE:0QNABasilea Pharmaceutica Ag
16/05/202407:15UK RegulatoryStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
16/05/202407:15UK RegulatoryStarke Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
03/05/202407:15UK RegulatoryBasilea berichtet über Präsentation neuer Daten zu Ceftobiprol (Zevtera®) auf dem Fachkongress ESCMID Global 2024LSE:0QNABasilea Pharmaceutica Ag
03/05/202407:15UK RegulatoryBasilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024LSE:0QNABasilea Pharmaceutica Ag
24/04/202418:00UK RegulatoryBasilea-Aktionäre genehmigen an der Generalversammlung alle Anträge des VerwaltungsratsLSE:0QNABasilea Pharmaceutica Ag
24/04/202418:00UK RegulatoryBasilea shareholders approve all proposals of the board of directors at the annual general meetingLSE:0QNABasilea Pharmaceutica Ag
09/04/202407:15UK RegulatoryBasilea erhält CARB-X-Förderung für die Entwicklung einer kürzlich erworbenen neuen Antibiotika-WirkstoffklasseLSE:0QNABasilea Pharmaceutica Ag
09/04/202407:15UK RegulatoryBasilea awarded CARB-X grant to develop recently acquired novel class of antibioticsLSE:0QNABasilea Pharmaceutica Ag
04/04/202407:15UK RegulatoryBasilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicationsLSE:0QNABasilea Pharmaceutica Ag
04/04/202407:15UK RegulatoryBasilea gibt Erhalt der US-FDA-Zulassung für Antibiotikum ZEVTERA® (Ceftobiprol-Medocaril) für drei Indikationen bekanntLSE:0QNABasilea Pharmaceutica Ag
11/03/202407:15UK RegulatoryContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
11/03/202407:15UK RegulatoryAnhaltend gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
13/02/202407:15UK RegulatoryBasilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolioLSE:0QNABasilea Pharmaceutica Ag
13/02/202407:15UK RegulatoryBasilea meldet starkes Gesamtjahr 2023 mit einer über der Guidance liegenden Profitabilität trotz substanziell erweitertem F&E-PortfolioLSE:0QNABasilea Pharmaceutica Ag
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:LSE:0QNA
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network